$5 Billion Bispecific Antibody Pharma Collaboration

Biopharma Akeso Inc. has announced it will enter into a collaboration potentially worth up to $5 billion with Summit Therapeutics Inc., by out-licensing its breakthrough bispecific antibody, ivonescimab for development and commercialisation in the US, Canada, Europe, and Japan.